论文部分内容阅读
对原发性肝癌（PHC）、肝硬化和其他消化道恶性肿瘤以及健康人进行了AFP、AFU、GPDA、LDL－VLDL－GGT、GGT和TBA等六项指标的检测。结果表明，PHC患者血清多指标含量与健康对照组和良性肝病组相比，均有显著性差异（P＜0．05），与其他消化道恶性肿瘤组相比，AFP、AFU、LDL－VLDL-GGT和TBA亦有显著性差异（P＜0．05）。各指标的灵敏度、特异性、阳性预期值、阴性预期值和实验总有效率以AFP为最佳，AFU次之。AFP阴性时，单项标志物的敏感度和特异性以AFU最高，表明对AFP阴性的PHC，AFU是一项较好的互补指标。三指标和四指标联合应用，虽可进一步提高灵敏度，但特异性、阳性结果预期值和实验总有效率均显著下降。
AFP, AFU, GPDA, LDL-VLDL-GGT, GGT and TBA were used to detect primary liver cancer (PHC), liver cirrhosis and other digestive tract malignancies as well as healthy individuals. The results showed that the serum levels of multiple indicators in PHC patients were significantly higher than those in healthy controls and benign liver diseases (P<0.05). Compared with other gastrointestinal cancers, AFP, AFU, and LDL-VLDL -GGT and TBA also had significant differences (P<0.05). The sensitivity, specificity, positive predictive value, negative predictive value, and total experimental efficiency of each index were best for AFP, followed by AFU. When AFP was negative, the sensitivity and specificity of the individual markers were highest in AFU, indicating that AFU is a good complementary indicator for AFP-negative PHC. The combined use of the three indicators and the four indicators can further increase the sensitivity, but the specificity, the expected value of positive results, and the total effective rate of the experiment are all significantly reduced.